Home / 2014 / February (page 8)

Monthly Archives: February 2014

Mechanisms and Receptors Controlling Intestinal GLP-1 Secretion, Part 2

David Joffe, BSPharm, CDE  Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy The molecular mechanisms linking fatty acids to GLP-1 secretion from gut endocrine cells remain incompletely understood. Hirasawa and colleagues have identified a GPCR, designated GPR120 that serves as a receptor for fatty acids on gut endocrine cells. …

Read More »

Exercise Log from dLife

Exercise Log from dLife Print out copies of this simple daily exercise log from dLife and start charting your patients’ progress to help them set fitness goals. Exercise Log from dLife  

Read More »

AliveCor® an EKG on Your Smart Phone

AliveCorimage

AliveCor® an EKG on Your Smart Phone  With the AliveCor System you can offer cardiac expertise to more of your patients, expanding the scope of your practice and providing valuable information about your patients’ cardiac health. The FDA has granted the company over-the-counter clearance for the AliveCor Heart Monitor, a …

Read More »

Two Elements from Grape Extract May Help to Treat Diabetes

Cyanidin and delphinidin, when encapsulated in nanoliposoms, decrease in vitro glycation of albumin and hemoglobin A. They also decrease blood glucose and blood cholesterol in diabetic mice. Iranian researchers investigated the effects of these materials in two forms of free and nanoliposomal on decreasing the damages caused by diabetes. Planta …

Read More »

Oral Insulin Capsules for Type 1

Oramed has submitted a protocol to the FDA to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The double-blind, randomized, placebo controlled, seven-day study design will be carried out at an inpatient setting on twenty-four type 1 diabetic patients. It’s hope …

Read More »

180 Diabetes Drugs in Development

America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development — all either in clinical trials or under review by the FDA — include 30 for type 1 diabetes, 100 for type 2 and 52 …

Read More »

Encapsulated Betacell Therapy

JDRF announces funding of $7 million to help ensure a rapid transition of ViaCyte’s VC-01 encapsulated cell therapy product into the clinical phase of development….

Read More »